uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
First-line and intensified treatment with glucose lowering drugs in the Swedish type 2 diabetes population
Karolinska Inst, Stockholm, Sweden..
AstraZeneca, Sodertalje, Sweden..
Karolinska Inst, Stockholm, Sweden..
Statisticon, Uppsala, Sweden..
Show others and affiliations
2015 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 58, no Suppl. 1, p. S181-S181Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
2015. Vol. 58, no Suppl. 1, p. S181-S181
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:uu:diva-264909ISI: 000359820901051OAI: oai:DiVA.org:uu-264909DiVA, id: diva2:867178
Conference
51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SEP 14-18, 2015, Stockholm, SWEDEN
Note

Meeting Abstract: 361

Available from: 2015-11-04 Created: 2015-10-19 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

By organisation
Department of Medical Sciences
In the same journal
Diabetologia
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 283 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf